Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM

Key Points

• Dimensional Fund Advisors cut its Tempus AI stake by 75.4% in the first quarter, selling 125,046 shares and retaining 40,833 shares worth approximately $1.85 million. Institutional investors and hedge funds own 24.22% of the company.
• Tempus AI reported quarterly adjusted losses of $0.04 per share, beating expectations of a $0.14 loss, while revenue rose 21.6% year over year to $382.49 million. Analysts have a consensus “Hold” rating and an average price target of $64.92.
• Company insiders have sold 743,981 shares worth about $35.9 million over the past quarter, including CEO Ryan Fukushima’s $1.0 million sale under a pre-arranged Rule 10b5-1 plan.

Dimensional Fund Advisors LP lessened its stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 75.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,833 shares of the company's stock after selling 125,046 shares during the period. Dimensional Fund Advisors LP's holdings in Tempus AI were worth $1,846,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in TEM. JPL Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new position in shares of Tempus AI during the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI in the third quarter valued at approximately $38,000. Whittier Trust Co. boosted its stake in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after purchasing an additional 570 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Tempus AI by 88.8% during the second quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company's stock worth $44,000 after buying an additional 325 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $54.29 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The company has a market cap of $9.80 billion, a price-to-earnings ratio of -37.70 and a beta of 3.58. The firm has a 50 day simple moving average of $51.68 and a 200 day simple moving average of $51.50.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm's revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. Research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. BTIG Research dropped their target price on shares of Tempus AI from $80.00 to $70.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Freedom Capital raised Tempus AI to a "hold" rating in a research report on Tuesday, June 30th. HC Wainwright reduced their price objective on shares of Tempus AI from $64.00 to $56.00 and set a "buy" rating for the company in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $64.92.

Insider Activity at Tempus AI

In other news, CEO Ryan Fukushima sold 20,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $50.04, for a total transaction of $1,000,800.00. Following the transaction, the chief executive officer owned 123,945 shares of the company's stock, valued at $6,202,207.80. This represents a 13.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the completion of the transaction, the director owned 25,942 shares in the company, valued at approximately $1,426,810. The trade was a 9.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 743,981 shares of company stock worth $35,880,242 over the last quarter. 24.26% of the stock is owned by company insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source